47 patents
Utility
Formulations of Bendamustine
16 Jan 24
Long term storage stable bendamustine-containing compositions are disclosed.
Nagesh R. Palepu, Philip Christopher Buxton
Filed: 14 Dec 22
Utility
Pemetrexed Formulations
11 Jan 24
The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C.
Feng-Jing CHEN, Steven L. KRILL
Filed: 20 Sep 23
Utility
Pemetrexed Formulations
11 Jan 24
The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C.
Feng-Jing CHEN, Steven L. KRILL
Filed: 20 Sep 23
Utility
Pemetrexed Formulations
28 Dec 23
The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C.
Feng-Jing CHEN, Steven L. KRILL
Filed: 28 Aug 23
Utility
Fulvestrant Formulations and Methods of Their Use
21 Dec 23
The present disclosure provides methods of treating breast cancer including administering aqueous suspensions com-prising solubilized fulvestrant, non-solubilized fulvestrant particles having one or more of an LD Dv(1 0) between about 1.5 and about 2.1 microns, an LD Dv(50) between about 5.5 and about 9.0 microns, and an LD Dv(90) between about 15 and about 35 microns, with the aqueous suspensions further including a surfactant, a polyvinylpyrrolidone, and a sugar alcohol, and a water-soluble excipient.
Feng-Jing CHEN, Steven L. KRILL, Rama Abu SHMEIS, Adrian HEPNER, Charles WESCOTT, Tara JASKOWSKI, Michael JOYCE
Filed: 14 Feb 23
Utility
Formulations of bendamustine
19 Dec 23
Long term storage stable bendamustine-containing compositions are disclosed.
Nagesh R. Palepu, Philip Christopher Buxton
Filed: 14 Dec 22
Utility
Pemetrexed Formulations
7 Dec 23
The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C.
Feng-Jing CHEN, Steven L. KRILL
Filed: 22 Aug 23
Utility
Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP)
21 Nov 23
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed.
Alyssa M. Larson, Alisha K. Weight, Kevin Love, Alan Crane, Robert S. Langer, Alexander M. Klibanov
Filed: 9 Oct 20
Utility
Pemetrexed formulations
24 Oct 23
The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C.
Feng-Jing Chen, Steven L Krill
Filed: 8 Jun 22
Utility
Formulations of Bendamustine
14 Sep 23
Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed.
Srikanth Sundaram
Filed: 5 Apr 23
Utility
Formulations of Bendamustine
3 Aug 23
Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed.
Srikanth Sundaram
Filed: 5 Apr 23
Utility
Methods of Treating Severe Acute Respiratory Syndrome
18 May 23
The disclosure is directed to methods of using dantrolene or a dantrolene prodrug, or a pharmaceutically acceptable salt thereof, to treat Severe Acute Respiratory Syndrome.
Adrian HEPNER
Filed: 8 Apr 21
Utility
Methods of Treating Viral Infections
18 May 23
The disclosure is directed to methods of using dantrolene or a dantrolene prodrug, or a pharmaceutically acceptable salt thereof, to treat viral infections.
Adrian HEPNER
Filed: 8 Apr 21
Utility
Use of Amisulpride As an Anti-emetic
11 May 23
Amisulpride is used in the therapy of nausea, vomiting or retches.
Julian Clive GILBERT, Robert William GRISTWOOD, Nicola COOPER, Gabriel FOX
Filed: 11 Jan 23
Utility
Methods of Treating Coronavirus Infections
11 May 23
The disclosure is directed to methods of using dantrolene or a dantrolene prodrug, or a pharmaceutically acceptable salt thereof, to treat coronavirus infections.
Adrian HEPNER
Filed: 8 Apr 21
Utility
Methods of Treating SARS-COV-2 Infections
11 May 23
The disclosure is directed to methods of using dantrolene or a dantrolene prodrug, or a pharmaceutically acceptable salt thereof, to treat COVID-19 and SARS-CoV-2 infections.
Adrian HEPNER
Filed: 8 Apr 21
Utility
Formulations of Bendamustine
13 Apr 23
Long term storage stable bendamustine-containing compositions are disclosed.
Nagesh R. Palepu, Philip Christopher Buxton
Filed: 14 Dec 22
Utility
Formulations of Bendamustine
13 Apr 23
Long term storage stable bendamustine-containing compositions are disclosed.
Nagesh R. Palepu, Philip Christopher Buxton
Filed: 14 Dec 22
Utility
Fulvestrant formulations and methods of their use
28 Feb 23
The present disclosure provides methods of treating breast cancer including administering aqueous suspensions comprising solubilized fulvestrant, non-solubilized fulvestrant particles having one or more of an LD Dv(10) between about 1.5 and about 2.1 microns, an LD Dv(50) between about 5.5 and about 9.0 microns, and an LD Dv(90) between about 15 and about 35 microns, with the aqueous suspensions further including a surfactant, a polyvinylpyrrolidone, and a sugar alcohol, and a water-soluble excipient.
Feng-Jing Chen, Steven L. Krill, Rama Abu Shmeis, Adrian Hepner, Charles Wescott, Tara Jaskowski, Michael Joyce
Filed: 8 Nov 18
Utility
Pemetrexed Formulations
5 Jan 23
The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C.
Feng-Jing CHEN, Steven L. KRILL
Filed: 30 Aug 22